Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Bart Friedman
AddedFeb 19, 2024
UpdatedMay 31, 2026
Bart Friedman

Bart Friedman

Board Member, Giant Eagle

LinkedInThe Org

Bart Friedman's Career

Giant Eagle
Giant Eagle

Pittsburgh, PA, US

Board Member· Board
Ovid Therapeutics
Ovid Therapeutics

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Bart Friedman's Career

Giant Eagle
Giant Eagle
Acquisition$1.6B13.6k1931Pittsburgh, PA, US
Board Member· Board

Leadership at Giant Eagle

Alexandra Wilkis WilsonAlexandra Wilkis WilsonBoard Member
Bill ArtmanBill ArtmanCEO
David ShapiraDavid ShapiraBoard Member

Similar to Giant Eagle

KrogerKrogerCincinnati, OH, USRetail, Supermarketsest. 1883KrogerCincinnati, OH, US · est. 1883

Leading American retail chain with supermarkets nationwide.

Public · $550M430k
MeijerMeijerGrand Rapids, MI, USGroceries, Retailest. 1934MeijerGrand Rapids, MI, US · est. 1934

Meijer Distribution, Inc.: A US-based hypermarket chain offering groceries, pharmaceuticals, electronics, clothing, and more.

Series A · $27M70k
Stop & ShopStop & ShopQuincy, MA, USFood, Groceriesest. 1914Stop & ShopQuincy, MA, US · est. 1914

Stop & Shop: A leading northeastern US supermarket chain, from humble 1892 beginnings to 406 stores.

Public · $400k82k
Weis MarketsWeis MarketsSunbury, PA, USFood Retailest. 1912Weis MarketsSunbury, PA, US · est. 1912

Weis Markets: A leading Mid-Atlantic food retailer with 200 stores across seven states.

Public23k
Ovid Therapeutics
Ovid Therapeutics
Public$184.1M402014New York City, NY, US
Board Member· Board

Leadership at Ovid Therapeutics

Jeremy LevinJeremy LevinCEO
Matthew DuringMatthew DuringBoard Member
Karen BernsteinKaren BernsteinBoard Member

Similar to Ovid Therapeutics

Oviva TherapeuticsOviva TherapeuticsNew York City, NY, USTherapeuticsest. 2021Oviva TherapeuticsNew York City, NY, US · est. 2021

Oviva Therapeutics: Advancing women's health through innovative biotech solutions in ovarian physiology.

Seed · $11.5M30
OmerosOmerosSeattle, WA, USTherapeuticsest. 1994OmerosSeattle, WA, US · est. 1994

Seattle-based Omeros develops and commercializes therapeutics for inflammation, coagulopathies, and CNS disorders.

Public · $972M196
NeuroPro TherapeuticsNeuroPro TherapeuticsYachats, OR, USPharmaceuticalsest. 2014NeuroPro TherapeuticsYachats, OR, US · est. 2014

NeuroPro Therapeutics: Developing pharmaceutical solutions for epilepsy and neurological disorders.

Series A · $5.1M5
Orphan Star TherapeuticsOrphan Star TherapeuticsNew York City, NY, USTherapiesest. 2017Orphan Star TherapeuticsNew York City, NY, US · est. 2017

Orphan Star Therapeutics: A NY-based biopharmaceutical firm developing therapies for rare diseases.

Series B · $20M5

Bart Friedman's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Bart Friedman

Gwill YorkGwill YorkBoard Member · SofinaJim MillsteinJim MillsteinBoard Member · MillsteinRay McGuireRay McGuireBoard Member · Hess CorporationRichard 'Rich' DeMartiniRichard 'Rich' DeMartiniBoard Member · Crestview PartnersEthan BeardEthan BeardBoard Member · ParchmentFrances FreiFrances FreiBoard Member · AboveBoard